The Pulmonary Arterial Hypertension (PAH) therapeutics market will experience modest growth from $3.45 billion in 2014 to $4.75 billion by 2024, representing a Compound Annual Growth Rate (CAGR) of 3.2%.

Vascular BioSciences announces the publication of "Vascular Histomolecular Analysis By Sequential Endoarterial Biopsy in a Shunt Model of Pulmonary Hypertension" to the current issue of the Pulmonary Circulation.

A recently published paper from Vascular Biosciences (VBS) has been selected by the Faculty of 1000 (F1000) as one of the top 2 percent of all published articles in the biological and medical sciences in 2011.